Estradiol and Bone Density: Prevention After Menopause

Estradiol restores the brake. On therapy, bone turnover falls back toward premenopausal rates, bone density stabilizes or rises, and fracture risk falls — the WHI's 33% reduction in hip fracture and 24% in total fracture, at the whole-population level, with the benefit appearing in women who had normal bone density at the start.

Two things make that distinctive. It is the only therapy that addresses the cause of postmenopausal bone loss rather than the consequence — bisphosphonates slow the breaking-down cells directly, but they do not restore the hormone whose absence set them loose. And it is preventive in a way the osteoporosis drugs are not licensed to be: they are used once bone density is already low; estrogen protects it before it falls.

The FDA's November 2025 label review acknowledged this directly, writing into the label that hormone therapy started within ten years of menopause is associated with fewer fractures. The women's HRT page covers the timing window.

The protection lasts as long as the estrogen does. Stop, and bone loss resumes at the postmenopausal rate — not faster, but not slower either. That is one of the honest arguments for continuing therapy longer in a woman whose bone is the main reason for it.

A DEXA scan measures bone density at the spine and hip and reports it against a young-adult reference. It is quick, low-radiation, and the only way to know where a woman is starting from.

We want one before estradiol in any woman with a reason to think her bone is already compromised: a prior fracture from a low-impact fall, a parent who broke a hip, early menopause or oophorectomy, long-term steroid use, low body weight, a history of restricted eating or amenorrhea — see the athlete bone page — or simply being over 65 without one on file. The result changes the plan: a normal scan means estradiol is prevention, while an osteoporotic scan means it is one part of treatment and a bone specialist is involved.

Weight loss unloads the skeleton, and a woman starting a GLP-1 without estrogen is losing bone-protective load at exactly the time her hormones have stopped protecting it. That combination is a specific reason for a baseline DEXA.

Alendronate and its relatives are the standard treatment for established osteoporosis, and estradiol does not replace them in that role. A woman with a fracture and an osteoporotic scan needs a bone specialist and, usually, a bone-specific drug; estradiol may run alongside it, and for a woman within the timing window it often should.

For the far larger group — women in the window with normal or mildly reduced density and menopausal symptoms — estradiol treats the symptoms and protects the bone at once, and a bisphosphonate is not indicated. The Menopause Society's position is that hormone therapy is appropriate for bone protection in women under 60 or within ten years of menopause, and that it is a reasonable choice for that purpose even when symptoms are not the main driver.

The osteoporosis drugs have their own long-term concerns — jaw osteonecrosis and atypical femoral fractures with prolonged use — that estradiol does not share. For a woman who wants to protect bone for the next twenty years, that comparison is worth knowing.